Matthew W. Rosinack serves as Interim Principal Financial Officer and Principal Accounting Officer at Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering T cell-based therapies for advanced cancers. Appointed to this role in May 2024, Rosinack oversees all aspects of financial reporting, accounting operations, internal controls, tax compliance, and SEC filings, ensuring the company's financial integrity amid its transition to commercialization following the FDA approval of Amtagvi™ (lifileucel), the first tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. His leadership provides critical stability as Iovance scales manufacturing, launches its first product, and pursues additional pipeline advancements. Rosinack joined Iovance in April 2021 as Vice President, Finance, rapidly advancing through roles that supported the company's pivotal Phase 3 trials, equity financings raising over $1 billion, and preparation for public market milestones. Prior to Iovance, he was Vice President, Finance at Turning Point Therapeutics, Inc., where he managed financial operations leading to its $4.1 billion acquisition by Bristol Myers Squibb in 2022. His career spans more than 25 years in life sciences finance, including senior positions at Relypsa, Inc. (acquired by Galénica for $1.3 billion), Nektar Therapeutics, and PDL BioPharma, where he honed expertise in GAAP compliance, investor relations, and strategic financial planning for high-growth biotechs. Rosinack's achievements include guiding multiple companies through IPOs, tender offers, and debt financings while implementing scalable ERP systems and SOX-compliant controls. A Certified Public Accountant with a B.S. in Accounting from San Diego State University, he has been recognized for fostering financial discipline that accelerates innovation, directly contributing to Iovance's momentum in delivering transformative TIL therapies to patients with metastatic melanoma and beyond.